Literature DB >> 11483076

Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years.

.   

Abstract

OBJECTIVE: To evaluate outcomes at 10 years after randomization for eyes undergoing cryotherapy vs eyes serving as controls, for patients enrolled in the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP).
METHODS: The randomized cohort originally consisted of 291 preterm children with birth weights less than 1251 g who developed a defined threshold of ROP severity in one or both eyes. Patients with bilateral threshold ROP (n = 240) were randomly assigned to receive cryotherapy to one eye and no cryotherapy to the other eye. Those with ROP of less severity than threshold in the fellow eye ("asymmetric"; n = 51) were randomly assigned to cryotherapy or no cryotherapy in the eye with threshold ROP. Ten years later, a tester who was masked to treatment status of each eye measured distance and near visual acuity, with "unfavorable" outcome being 20/200 or worse. Patients also were evaluated by study-certified ophthalmologists who assessed ROP residua primarily in the posterior pole of the fundus, with unfavorable outcome being a posterior retinal fold or worse.
RESULTS: For the 247 children examined, both functional and structural primary outcomes showed fewer unfavorable outcomes in treated vs control eyes: 44.4% vs 62.1% (P<.001) for distance visual acuity and 27.2% vs 47.9% (P<.001) for fundus status. Near acuity results were similar to those for distance (42.5% vs 61.6%; P<.001). Total retinal detachments had continued to occur in control eyes, increasing from 38.6% at 5(1/2) years to 41.4% at 10 years, while treated eyes remained stable (at 22.0%). A previously disturbing subgroup trend that more control eyes than treated eyes had visual acuity of 20/40 or better (in the 5(1/2)-year report) was no longer present at 10 years; eyes that received cryotherapy were found at least as likely as control eyes to have 20/40 or better visual acuity.
CONCLUSIONS: At 10 years, eyes that had received cryotherapy were much less likely than control eyes to be blind. A previous trend for a higher proportion of sighted control eyes than sighted treated eyes to show acuity in the normal range was not confirmed. The results show long-term value from cryotherapy in preserving visual acuity in eyes with threshold ROP.

Entities:  

Mesh:

Year:  2001        PMID: 11483076     DOI: 10.1001/archopht.119.8.1110

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  74 in total

1.  Blindness in children.

Authors:  Clare Gilbert; Haroon Awan
Journal:  BMJ       Date:  2003-10-04

2.  The nine lives of retinopathy of prematurity.

Authors:  W V Good
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

3.  Ophthaproblem. Retinopathy of prematurity.

Authors:  Clara Chan; Alan F Cruess; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2003-12       Impact factor: 3.275

4.  What do you do about ROP screening in "big" babies?

Authors:  G E Quinn
Journal:  Br J Ophthalmol       Date:  2002-10       Impact factor: 4.638

5.  [Comparison of the anatomical and functional outcome after laser or cryotherapy for retinopathy of prematurity (ROP)].

Authors:  C Jandeck; U Kellner; H Heimann; M H Foerster
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059

6.  Variations in the morphology of retinopathy of prematurity in extremely low birthweight infants.

Authors:  W E Schulenburg; G Tsanaktsidis
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

7.  Threshold ROP.

Authors:  D Clark
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

8.  Inflammation and retinopathy of prematurity.

Authors:  Olaf Dammann
Journal:  Acta Paediatr       Date:  2010-04-16       Impact factor: 2.299

9.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004

10.  Posterior to the ridge laser treatment for severe stage 3 retinopathy of prematurity.

Authors:  A L Ells; G A Gole; P Lloyd Hildebrand; A Ingram; C M Wilson; R Geoff Williams
Journal:  Eye (Lond)       Date:  2013-01-18       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.